Indian banking stocks faced significant selling pressure on 20 July 2026, with the Nifty banks index falling 1% as private lenders reported disappointing quarterly results. According to Reuters, HDFC Bank led the decline with a more than 5% drop as weaker-than-expected lending margins raised profitability concerns. The Nifty 50 declined 0.4% while private bank shares fell 2.3% and financials dropped 1.2%. Private lenders including HDFC Bank, ICICI Bank, Axis Bank, and Kotak Mahindra Bank reported strong loan growth but margins came under pressure due to greater competition and higher funding costs. As per Jefferies, HDFC Bank was relatively weaker among major private lenders this quarter, with its net interest margin standing at 3.26%, below the 4% level before its merger with parent HDFC in 2023.
Market expert Raja Venkatraman from NeoTrader has recommended three stocks for trading on 21 July 2026 despite the challenging banking sector environment. As reported by Mint, his picks include AMBUJACEM (CMP ₹437.80), ANTHEM (CMP ₹791.55), and FIVESTAR (CMP ₹570.50). Venkatraman's technical analysis suggests buying opportunities above specific price levels with defined stop-loss and target prices for each stock.
AMBUJACEM is recommended with a buy above ₹441 and stop loss at ₹428 targeting ₹479 within 2 months. According to Mint, the stock has slipped into rangebound action after continued selling pressure but received a Bernstein upgrade to 'Outperform' from 'Market Perform' on July 2, citing the valuation gap between India's two largest cement producers as unsustainable. The stock shows P/E ratio of 30.53, 52-week high of ₹625, and volume of 1.5M with technical support at ₹400 and resistance at ₹500.
ANTHEM is recommended for buy above ₹792 with stop loss at ₹760 targeting ₹870 within 2 months. As reported by Mint, the innovation-driven Contract Research, Development, and Manufacturing Organization has shown range breakout after consolidation, with P/E ratio of 66.50, 52-week high of ₹873.25, and volume of 1.25M. FIVESTAR is recommended for buy above ₹573 with stop loss at ₹530 targeting ₹625 within 2 months. The Chennai-headquartered NBFC shows P/E ratio of 15.33, 52-week high of ₹737.05, and volume of 760.06K.
According to Mint, the technical setup reveals a 'confused' trend with formation of lower lows taking away many market participants. Venkatraman notes that higher levels continue to be a selling zone, making recovery challenging. Key risk factors include volatile energy prices, intense industry competition, cyclical rural demand, and stringent climate regulations for cement companies, while high stock valuation, ongoing high capital expenditure, customer-concentration risks, and regulatory scrutiny pose challenges for biotech and NBFC sectors. The expert advises being selective in approach given the current market conditions and geopolitical uncertainties.
